The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

Mounjaro has been on the FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.

The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday. Mounjaro has been on the FDA's shortage ...

Lilly has started selling vials of the lowest dose of Zepbound in U.S. through its direct-to-consumer website to improve availability and combat the rise in popularity of compounded versions.

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Related Lilly cuts price on weight-loss drug Zepbound, selling it in single-dose vials Decision on new Lilly Alzheimer's drug delayed by FDA Eli Lilly names new head of diabetes and obesity ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.